Study suggests 2004 lawsuit fueled big spending on epilepsy drugs

Oct 30 2012

Reuters: Did the Neurontin Lawsuit Fuel Health Spending?
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses. Now, a study in the Journal of Clinical Psychiatry questions whether the lawsuit ended up fueling spending on other epilepsy drugs instead of curbing so-called off-label prescribing (Joelving, 10/26).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Medical Condition News | Healthcare News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options
Expanded access to weight-loss drugs could save thousands of lives
Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing
Aircraft noise pollution harms arteries, but heart drugs show promise in animal model research
Triptans better at relieving migraine pain than recently marketed and more expensive drugs
Holistic lifestyle interventions outshine drugs in preventing cardiometabolic diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation